CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Nitrosative stress drives heart failure with preserved ejection fraction When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors The year in cardiovascular medicine 2020: heart failure and cardiomyopathies Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol

Editorial17 Nov 201

JOURNAL:Circulation. Article Link

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez FA, Serenelli M, Nicolau JC et al. Keywords: dapagliflozin; HFrEF; efficacy; safety

FULL TEXT PDF